PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...

If approved, aripiprazole 2-month ready-to-use (RTU), long-acting injectable (LAI) would be the first 2-month, LAI antipsychotic indicated for both treatment of schizophrenia and the maintenance ...

Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...

Aristada (aripiprazole lauroxil) is a prescription drug that’s used to treat schizophrenia. Aristada is given by a healthcare professional as an injection into a muscle. Aristada is used as a ...

Otsuka Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Company announced today that the US FDA approved the supplemental New Drug Application for ABILIFY for the acute treatment of manic and mixed ...

TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved ...

Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a new drug application for aripiprazole, a 2-month, ready-to-use, long-acting injectable ...